(Q44963255)

7 December 2017

title

Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis (English)

1 reference

7 December 2017

1 reference

1 reference

Lopez-Sanroman A

1

1 reference

7 December 2017

Bermejo F

series ordinal

2

1 reference

7 December 2017

Carrera E

series ordinal

3

1 reference

7 December 2017

Garcia-Plaza A

series ordinal

4

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Alimentary Pharmacology & Therapeutics

7 December 2017

published in

1 reference

7 December 2017

volume

20

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

161-166

1 reference

Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02030.X

10.1111/J.1365-2036.2004.02030.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference